CZ353698A3 - Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje - Google Patents

Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje Download PDF

Info

Publication number
CZ353698A3
CZ353698A3 CZ983536A CZ353698A CZ353698A3 CZ 353698 A3 CZ353698 A3 CZ 353698A3 CZ 983536 A CZ983536 A CZ 983536A CZ 353698 A CZ353698 A CZ 353698A CZ 353698 A3 CZ353698 A3 CZ 353698A3
Authority
CZ
Czechia
Prior art keywords
antibody
seq
sequence
light chain
humanized
Prior art date
Application number
CZ983536A
Other languages
Czech (cs)
English (en)
Inventor
Clive Graham Copley
Michael Derek Edge
Stephen Charles Emery
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609405.7A external-priority patent/GB9609405D0/en
Priority claimed from GBGB9703103.3A external-priority patent/GB9703103D0/en
Application filed by Zeneca Limited filed Critical Zeneca Limited
Publication of CZ353698A3 publication Critical patent/CZ353698A3/cs

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
CZ983536A 1996-05-04 1997-04-29 Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje CZ353698A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609405.7A GB9609405D0 (en) 1996-05-04 1996-05-04 Protein
GBGB9703103.3A GB9703103D0 (en) 1997-02-14 1997-02-14 Protein

Publications (1)

Publication Number Publication Date
CZ353698A3 true CZ353698A3 (cs) 1999-02-17

Family

ID=26309272

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ983536A CZ353698A3 (cs) 1996-05-04 1997-04-29 Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje

Country Status (19)

Country Link
US (2) US6277599B1 (enExample)
EP (1) EP0896626B1 (enExample)
JP (1) JP2000510692A (enExample)
CN (1) CN1217750A (enExample)
AT (1) ATE350478T1 (enExample)
AU (1) AU719513B2 (enExample)
BR (1) BR9708910A (enExample)
CA (1) CA2250579A1 (enExample)
CZ (1) CZ353698A3 (enExample)
DE (1) DE69737188T2 (enExample)
ES (1) ES2279539T3 (enExample)
HU (1) HUP9901562A3 (enExample)
IL (1) IL126772A0 (enExample)
NO (1) NO985120L (enExample)
NZ (1) NZ331978A (enExample)
PL (1) PL329871A1 (enExample)
SK (1) SK150298A3 (enExample)
TR (1) TR199802227T2 (enExample)
WO (1) WO1997042329A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2279539T3 (es) * 1996-05-04 2007-08-16 Astrazeneca Ab Anticuerpo monoclonal anti-cea, conjugados que comprenden dicho anticuerpo, y su uso terapeutico en un sistema adept.
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
CA2321947A1 (en) * 1998-02-25 1999-09-02 The Dow Chemical Company High affinity humanized anti-cea monoclonal antibodies
JP2002530080A (ja) * 1998-11-19 2002-09-17 インサイト・ファーマスーティカルズ・インコーポレイテッド 免疫グロブリン・スーパーファミリー・タンパク質
JP2002533072A (ja) * 1998-12-21 2002-10-08 イーライ・リリー・アンド・カンパニー β−リポトロピンおよび他のペプチドの組換え合成
CN1423660A (zh) * 1999-11-18 2003-06-11 牛津生物医学（英国）有限公司 抗体
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
ATE372130T1 (de) * 2000-04-22 2007-09-15 Pharmedartis Gmbh Apoptotika
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
KR100604037B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 경쇄 카파 발현벡터
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
US20070009957A1 (en) * 2003-03-04 2007-01-11 Alexion Pharmaceuticals, Inc. Vectors used to create hybrid constant regions
CN1795010A (zh) * 2003-04-23 2006-06-28 梅达雷克斯公司 针对α干扰素受体－1(IFNAR－1)的人源化抗体
EP1691763A4 (en) * 2003-12-12 2008-03-12 Genencor Int MOLECULES CAB
EP1716179A2 (en) 2004-02-12 2006-11-02 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
WO2005111078A2 (en) * 2004-04-15 2005-11-24 Genencor International, Inc. Anti-cea scfv-beta-lactamase contructs (cab molecules) in adept
EP2366717A3 (en) 2004-10-29 2011-12-14 University of Southern California Combination Cancer Immunotherapy with Co-Stimulatory Molecules
EP2322560B1 (en) 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
WO2006116592A2 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
US20080248048A1 (en) 2005-09-30 2008-10-09 Astrazeneca Ab Interleukin-13 Antibody Composition
JP2010500967A (ja) 2006-07-20 2010-01-14 ザ ジェネラル ホスピタル コーポレイション コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット
US8043830B2 (en) * 2008-02-01 2011-10-25 The Regents Of The University Of California Biotin-ligase system for secretion of biotinylated protein
CN101607985B (zh) * 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
CN101704892B (zh) * 2009-12-09 2014-02-12 中国人民解放军军事医学科学院生物工程研究所 一种抗uPAR人源化抗体及其编码基因与应用
UA104663C2 (xx) * 2010-01-28 2014-02-25 Глаксо Груп Лимитед Антитіло, що зв'язує cd127$антитело, связывающее cd127
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
BR112014009925B1 (pt) 2011-10-28 2022-09-20 Teva Pharmaceuticals Australia Pty Ltd Construtores de polipeptídeos e seus usos
CN102526707B (zh) * 2012-01-13 2015-04-22 成都博发生物技术有限公司 共刺激因子及融合蛋白的新用途
RU2493166C1 (ru) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
CN102838676A (zh) * 2012-09-26 2012-12-26 李彬 一种癌胚抗原单抗及包含该抗体的芯片以及应用
SI2766048T1 (sl) 2012-10-12 2015-03-31 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
DK3677591T5 (da) 2013-04-29 2024-08-26 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2015337858B2 (en) 2014-10-29 2020-09-24 Teva Pharmaceuticals Australia Pty Ltd. Interferon alpha2b variants
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
US11618784B2 (en) 2016-07-19 2023-04-04 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD47 combination therapy
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CN111533805B (zh) * 2016-12-04 2022-02-08 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的高亲和力纳米抗体及其应用
US20220111065A1 (en) 2018-05-23 2022-04-14 Adc Therapeutics Sa Molecular adjuvant
JP7548587B2 (ja) 2018-09-07 2024-09-10 アイタブメッド （エイチケイ） リミテッド 二重特異性抗原結合タンパク質及びその使用
WO2021041725A1 (en) * 2019-08-27 2021-03-04 The Trustees Of The Univeristy Of Pennsylvania SYNTHETIC CARS TO TREAT IL13Rα2 POSITIVE HUMAN AND CANINE TUMORS
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN115850483B (zh) * 2020-10-21 2025-09-19 北京纽安博生物技术有限公司 抗CEACAM6单域抗体、人源化单域抗体及其Fc融合蛋白和应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
EP0754225A4 (en) * 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
ES2279539T3 (es) * 1996-05-04 2007-08-16 Astrazeneca Ab Anticuerpo monoclonal anti-cea, conjugados que comprenden dicho anticuerpo, y su uso terapeutico en un sistema adept.

Also Published As

Publication number Publication date
DE69737188D1 (de) 2007-02-15
US6277599B1 (en) 2001-08-21
NZ331978A (en) 2000-05-26
EP0896626A1 (en) 1999-02-17
BR9708910A (pt) 1999-08-03
AU719513B2 (en) 2000-05-11
DE69737188T2 (de) 2007-10-11
CA2250579A1 (en) 1997-11-13
US20020142359A1 (en) 2002-10-03
EP0896626B1 (en) 2007-01-03
AU2645597A (en) 1997-11-26
NO985120L (no) 1998-12-29
ATE350478T1 (de) 2007-01-15
IL126772A0 (en) 1999-08-17
JP2000510692A (ja) 2000-08-22
HUP9901562A3 (en) 2000-06-28
US6903203B2 (en) 2005-06-07
NO985120D0 (no) 1998-11-03
TR199802227T2 (xx) 2000-07-21
ES2279539T3 (es) 2007-08-16
CN1217750A (zh) 1999-05-26
SK150298A3 (en) 1999-04-13
WO1997042329A1 (en) 1997-11-13
HUP9901562A2 (hu) 1999-08-30
PL329871A1 (en) 1999-04-12

Similar Documents

Publication Publication Date Title
AU719513B2 (en) Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
AU709503B2 (en) Delivery system using mAb 3E10 and mutants and/or functional fragments thereof
CA2019559C (en) Bispecific and oligospecific mono- and oligovalent receptors, the preparation and use thereof
JP4773097B2 (ja) ヒトインスリン受容体を介する医薬品の送達
KR101370164B1 (ko) 신규 항ｃｄ98 항체
KR100508136B1 (ko) 화합물
EP0731838B1 (en) Binding structures directed against the ca55.1 antigen
JP3805365B2 (ja) 化合物
AU2004245038A1 (en) De-immunized anti-CD3 antibody
CA2560919A1 (en) Uses of anti-ctla-4 antibodies
Hoogenboom et al. Cloning and expression of a chimeric antibody directed against the human transferrin receptor.
JPH11511970A (ja) 化学化合物
KR20000010771A (ko) Cea에 대한 모노클로널 항체, 이 항체를 함유하는 접합체 및adept계에서의 치료적 용도
JPH03254691A (ja) 薬剤耐性癌に対するキメラ抗体およびその製造
CZ396599A3 (cs) Genový konstrukt, který kóduje část zaměřující buňku a enzym aktivující proléčivo, pro použití jako léčivo

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic